Abstract:The cellular prion protein, PrP C , has been postulated to function as a receptor for α-synuclein, potentially facilitating cell-to-cell spreading and/or toxicity of α-synuclein aggregates in neurodegenerative disorders such as Parkinson's disease. Previously, we generated the "Salt (S)" and "No Salt (NS)" strains of α-synuclein aggregates that cause distinct pathological phenotypes in M83 transgenic mice overexpressing A53T-mutant human α-synuclein. To test the hypothesis that PrP C facilitates the propagation of α-synuclein aggregates, we produced M83 mice that either express or do not express PrP C . Following intracerebral inoculation with the S or NS strain, the absence of PrP C in M83 mice did not prevent disease development and had minimal influence on α-synuclein strain-specified attributes such as the extent of cerebral α-synuclein deposition, selective targeting of specific brain regions and cell types, the morphology of induced α-synuclein deposits, and the structural fingerprints of protease-resistant α-synuclein aggregates. Likewise, there were no appreciable differences in disease manifestation between PrP C -expressing and PrP C -lacking M83 mice following intraperitoneal inoculation of the S strain. Interestingly, intraperitoneal inoculation with the NS strain resulted in two distinct disease phenotypes, indicative of α-synuclein strain evolution, but this was also independent of PrP C expression. Overall, these results suggest that PrP C plays at most a minor role in the propagation, neuroinvasion, and evolution of α-synuclein strains in mice that express A53T-mutant human α-synuclein. Thus, other putative receptors or cell-to-cell propagation mechanisms may have a larger effect on the spread of α-synuclein aggregates during disease. During Parkinson's disease and related neurodegenerative disorders, the protein α-synuclein clumps together in the brain to form aggregates. α-Synuclein aggregates can spread between cells, and this process is believed to underlie disease progression. Thus, blocking the spread of α-synuclein aggregates may be a good therapeutic strategy for preventing the progression of Parkinson's disease. The details of how α-synuclein aggregates spread from cell to cell in the brain remain unclear, but it has been proposed that the cellular prion protein (PrP C ) may facilitate spreading by acting as a receptor for α-synuclein aggregates. However, this notion remains controversial. In this study, we compared the spread of α-synuclein aggregates within and to the brain in mice that either possessed or lacked PrP C . We found that the spreading of α-synuclein aggregates was largely independent of the presence of PrP C . This suggests that PrP C may not be an effective therapeutic target for attenuating the spread of α-synuclein aggregates in Parkinson's disease.

A-synuclein prion strains differentially adapt after passage in mice

The role of α-synuclein prion strains in Parkinson's disease and multiple system atrophy

A multiverse of α-synuclein: investigation of prion strain properties with carboxyl-terminal truncation specific antibodies in animal models

α-Synuclein Strain Propagation is Independent of Cellular Prion Protein Expression in Transgenic Mice

Unique seeding profiles and prion-like propagation of synucleinopathies are highly dependent on the host in human α-synuclein transgenic mice

α-Synuclein strain propagation is independent of cellular prion protein expression in a transgenic synucleinopathy mouse model

MSA prions exhibit remarkable stability and resistance to inactivation

Multiple steps of prion strain adaptation to a new host

Species barrier as molecular basis for adaptation of synthetic prions with N‐terminally truncated PrP

Carboxyl truncation of α-synuclein occurs early and is influenced by human APOE genotype in transgenic mouse models of α-synuclein pathogenesis

Selective neuronal targeting in prion disease

Distinct Α-Synuclein Strains Differentially Promote Tau Inclusions in Neurons.

Phosphorylation Induces Distinct Alpha-Synuclein Strain Formation

Is Multiple System Atrophy a Prion-like Disorder?

Prion Protein Misfolding, Strains, and Neurotoxicity: An Update from Studies on Mammalian Prions

Effects of the Pathogenic Mutation A117V and the Protective Mutation H111S on the Folding and Aggregation of PrP106-126: Insights from Replica Exchange Molecular Dynamics Simulations.

A New Cell Model for Investigating Prion Strain Selection and Adaptation

Cofactor and glycosylation preferences for in vitro prion conversion are predominantly determined by strain conformation

Convergent generation of atypical prions in knockin mouse models of genetic prion disease

Environmental and host factors that contribute to prion strain evolution

Region-specific glial homeostatic signature in prion diseases is replaced by a uniform neuroinflammation signature, common for brain regions and prion strains with different cell tropism